Expression of matriptase and clinical outcome of human endometrial cancer

Keiichiro Nakamura, Atsushi Hongo, Junichi Kodama, Fernando Abarzua, Yasutomo Nasu, Hiromi Kumon, Yuji Hiramatsu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Matriptase, a type II transmembrane serine protease is involved in angiogenesis, degradation of extracellular matrix and in progression of some epithelial cancers. The purpose of the present study was to examine matriptase expression and evaluate its clinicopathological significance in endometrial cancer. Patients and Methods: Matriptase expression was examined in normal endometrium (n=20), endometrial hyperplasia (n=11) and endometrial cancer (n=65) samples. The distribution of cases that scored positive for each of the biological parameters examined was correlated with matriptase expression status obtained by immunohistochemistry. Results: Matriptase was found to be significantly overexpressed in endometrial cancer as compared with normal endometrium and endometrial hyperplasia. Interestingly, matriptase expression is associated with stage (p=0.010), grade (p=0.021), depth of myometrial invasion (p=0.004), cervical involvement (p=0.021), lymph node metastasis (p=0.009), LVS involvement (p=0.041) and peritoneal cytology (p=0.045). The high matriptase expression was a significant predictor for poor prognosis when compared with low matriptase expression (Disease-free survival rate; p=0.032, Overall survival rate; p=0.011). Conclusion: High matriptase expression in endometrial cancer may be associated with poor prognosis.

Original languageEnglish
Pages (from-to)1685-1690
Number of pages6
JournalAnticancer Research
Volume29
Issue number5
Publication statusPublished - May 2009

Fingerprint

Endometrial Neoplasms
Endometrial Hyperplasia
Endometrium
Survival Rate
matriptase
Serine Proteases
Disease-Free Survival
Extracellular Matrix
Cell Biology
Lymph Nodes
Immunohistochemistry
Neoplasm Metastasis

Keywords

  • Endometrial cancer
  • Matriptase
  • Prognostic significance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nakamura, K., Hongo, A., Kodama, J., Abarzua, F., Nasu, Y., Kumon, H., & Hiramatsu, Y. (2009). Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Research, 29(5), 1685-1690.

Expression of matriptase and clinical outcome of human endometrial cancer. / Nakamura, Keiichiro; Hongo, Atsushi; Kodama, Junichi; Abarzua, Fernando; Nasu, Yasutomo; Kumon, Hiromi; Hiramatsu, Yuji.

In: Anticancer Research, Vol. 29, No. 5, 05.2009, p. 1685-1690.

Research output: Contribution to journalArticle

Nakamura, K, Hongo, A, Kodama, J, Abarzua, F, Nasu, Y, Kumon, H & Hiramatsu, Y 2009, 'Expression of matriptase and clinical outcome of human endometrial cancer', Anticancer Research, vol. 29, no. 5, pp. 1685-1690.
Nakamura K, Hongo A, Kodama J, Abarzua F, Nasu Y, Kumon H et al. Expression of matriptase and clinical outcome of human endometrial cancer. Anticancer Research. 2009 May;29(5):1685-1690.
Nakamura, Keiichiro ; Hongo, Atsushi ; Kodama, Junichi ; Abarzua, Fernando ; Nasu, Yasutomo ; Kumon, Hiromi ; Hiramatsu, Yuji. / Expression of matriptase and clinical outcome of human endometrial cancer. In: Anticancer Research. 2009 ; Vol. 29, No. 5. pp. 1685-1690.
@article{32f2deb239c8431c8998bc3bb17de4da,
title = "Expression of matriptase and clinical outcome of human endometrial cancer",
abstract = "Background: Matriptase, a type II transmembrane serine protease is involved in angiogenesis, degradation of extracellular matrix and in progression of some epithelial cancers. The purpose of the present study was to examine matriptase expression and evaluate its clinicopathological significance in endometrial cancer. Patients and Methods: Matriptase expression was examined in normal endometrium (n=20), endometrial hyperplasia (n=11) and endometrial cancer (n=65) samples. The distribution of cases that scored positive for each of the biological parameters examined was correlated with matriptase expression status obtained by immunohistochemistry. Results: Matriptase was found to be significantly overexpressed in endometrial cancer as compared with normal endometrium and endometrial hyperplasia. Interestingly, matriptase expression is associated with stage (p=0.010), grade (p=0.021), depth of myometrial invasion (p=0.004), cervical involvement (p=0.021), lymph node metastasis (p=0.009), LVS involvement (p=0.041) and peritoneal cytology (p=0.045). The high matriptase expression was a significant predictor for poor prognosis when compared with low matriptase expression (Disease-free survival rate; p=0.032, Overall survival rate; p=0.011). Conclusion: High matriptase expression in endometrial cancer may be associated with poor prognosis.",
keywords = "Endometrial cancer, Matriptase, Prognostic significance",
author = "Keiichiro Nakamura and Atsushi Hongo and Junichi Kodama and Fernando Abarzua and Yasutomo Nasu and Hiromi Kumon and Yuji Hiramatsu",
year = "2009",
month = "5",
language = "English",
volume = "29",
pages = "1685--1690",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Expression of matriptase and clinical outcome of human endometrial cancer

AU - Nakamura, Keiichiro

AU - Hongo, Atsushi

AU - Kodama, Junichi

AU - Abarzua, Fernando

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Hiramatsu, Yuji

PY - 2009/5

Y1 - 2009/5

N2 - Background: Matriptase, a type II transmembrane serine protease is involved in angiogenesis, degradation of extracellular matrix and in progression of some epithelial cancers. The purpose of the present study was to examine matriptase expression and evaluate its clinicopathological significance in endometrial cancer. Patients and Methods: Matriptase expression was examined in normal endometrium (n=20), endometrial hyperplasia (n=11) and endometrial cancer (n=65) samples. The distribution of cases that scored positive for each of the biological parameters examined was correlated with matriptase expression status obtained by immunohistochemistry. Results: Matriptase was found to be significantly overexpressed in endometrial cancer as compared with normal endometrium and endometrial hyperplasia. Interestingly, matriptase expression is associated with stage (p=0.010), grade (p=0.021), depth of myometrial invasion (p=0.004), cervical involvement (p=0.021), lymph node metastasis (p=0.009), LVS involvement (p=0.041) and peritoneal cytology (p=0.045). The high matriptase expression was a significant predictor for poor prognosis when compared with low matriptase expression (Disease-free survival rate; p=0.032, Overall survival rate; p=0.011). Conclusion: High matriptase expression in endometrial cancer may be associated with poor prognosis.

AB - Background: Matriptase, a type II transmembrane serine protease is involved in angiogenesis, degradation of extracellular matrix and in progression of some epithelial cancers. The purpose of the present study was to examine matriptase expression and evaluate its clinicopathological significance in endometrial cancer. Patients and Methods: Matriptase expression was examined in normal endometrium (n=20), endometrial hyperplasia (n=11) and endometrial cancer (n=65) samples. The distribution of cases that scored positive for each of the biological parameters examined was correlated with matriptase expression status obtained by immunohistochemistry. Results: Matriptase was found to be significantly overexpressed in endometrial cancer as compared with normal endometrium and endometrial hyperplasia. Interestingly, matriptase expression is associated with stage (p=0.010), grade (p=0.021), depth of myometrial invasion (p=0.004), cervical involvement (p=0.021), lymph node metastasis (p=0.009), LVS involvement (p=0.041) and peritoneal cytology (p=0.045). The high matriptase expression was a significant predictor for poor prognosis when compared with low matriptase expression (Disease-free survival rate; p=0.032, Overall survival rate; p=0.011). Conclusion: High matriptase expression in endometrial cancer may be associated with poor prognosis.

KW - Endometrial cancer

KW - Matriptase

KW - Prognostic significance

UR - http://www.scopus.com/inward/record.url?scp=67650073220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650073220&partnerID=8YFLogxK

M3 - Article

C2 - 19443387

AN - SCOPUS:67650073220

VL - 29

SP - 1685

EP - 1690

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -